Commercial Products

 

Vernalis Therapeutics, Inc. launched its first product in the US prescription market, Tuzistra® XR (codeine polistirex and chlorpheniramine polistirex) an extended-release CIII cough cold liquid.  The Company also acquired the US rights to Moxatag®, a once-a-day amoxicillin for strep throat in adult and pediatric patients 12 years of age or older. 

Click here for full Prescribing Information for Tuzistra® XR, including Boxed Warning and here for the Medication Guide.

Click here for full Prescribing Information for Moxatag®.

Click here for more information on our pipeline.

 

 

 

 

 

Latest News

Results Announcement for the year ended 30 June 2017

Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017.

Read more ...

Fact Sheet

For more information on Vernalis, click below to download a copy of our fact sheet

 

Factsheet-Nov14

 

 

 

 

Contact Vernalis Therapeutics

T: 1-484-913-0700
F: 1-610-651 5976

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch